AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34285701
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment with metformin only)
Trial: 35394723
Drug: Alental cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alental cream
Trial: 35394723
Drug: Aertal cream
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aertal cream
Trial: 34458708
Drug: Pooled RT-qPCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled RT-qPCR testing using oropharyngeal swabs or buccal swabs
Trial: 35501931
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) treatment initiated one day post-injury
Trial: 35501931
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) treatment
Trial: 35272249
Drug: Dry-needling together
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry-needling together with exercise therapy (DNG)
Trial: 33222767
Drug: MD1003 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD1003 (oral biotin 100 mg three times daily)
Trial: 33161105
Drug: Probucol combined
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol combined with mecobalamin tablets
Trial: 33161105
Drug: Control (mecobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (mecobalamin tablets only)
Trial: 35484429
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 10 IU/h
Trial: 35484429
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 5 IU/h
Trial: 35484429
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 2.5 IU/h
Trial: 34616527
Drug: Conventional acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acute angina pectoris drugs
Trial: 33863746
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment (n=17)
Trial: 34588252
Drug: Mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (50 mg orally once a day)
Trial: 35393934
Drug: Brief behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief behavioral treatment for insomnia (BBTI, 4 sessions)
Trial: 35393934
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation therapy (active control)
Trial: 35360485
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine hot ironing technique intervention
Trial: 37244291
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin supplement (Centrum Silver)
Trial: 34556107
Drug: Chitosan-based varnish
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan-based varnish (UNO Gel Bioschell, Germiphene corp.) applied weekly for 6 weeks
Trial: 34556107
Drug: Chlorhexidine-fluoride varnish
RxNorm normalized name: chlorhexidine / sodium fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-fluoride varnish (Cervitec F, Ivoclar Vivadent) applied weekly for 6 weeks
Trial: 32215834
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg daily for 1 week
Trial: 36089229
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP, 4 intra-articular saline injections over 8 weeks)
Trial: 34532299
Drug: Rifaximin, 550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin, 550 mg twice daily
Trial: 34790373
Drug: Carbon nanoparticles
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon nanoparticles suspension injections (CNS) administered endoscopically within 24 hours prior to neoadjuvant chemotherapy (NCT).
Trial: 35732064
Drug: Higher Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Brain Living (HBL) therapy
Trial: 36066854
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d of trans-resveratrol (RSV) for 3 months (90 days)
Trial: 36066854
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d of trans-resveratrol (RSV)
Trial: 616631076
Drug: lienal polypeptide
RxNorm normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lienal polypeptide injection combined with chemotherapy
Trial: 616631076
Drug: chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy only
Trial: 35695582
Drug: Mirtazapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (mean dosage = 39.56 mg/day)
Trial: 33601937
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) [Octagam 5%]
Trial: 32398120
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment algorithm based on ultrasonographic examination
Trial: 32398120
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (Control group A)
Trial: 32398120
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (Control group B)
Trial: 33165168
Drug: PGx‐treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGx‐treatment group (200 mg isoniazid)
Trial: 33165168
Drug: Standard‐treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐treatment group (300 mg isoniazid)
Trial: 33165168
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (300 mg isoniazid for NAT2 rapid acetylators)
Trial: 35314092
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment (specific dosage and duration not mentioned)
Trial: 36266402
Drug: 1-week residential
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week residential group program based on mindfulness training, artistic expression, and EMDR group therapy
Trial: 33099934
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg/3 weeks
Trial: 33099934
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg/3 weeks with primary surgery
Trial: 33099934
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg/3 weeks with secondary debulking surgery
Trial: 33008855
Drug: 2-event regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-event regimen (2 pills per day)
Trial: 33008855
Drug: 3-event regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-event regimen (3 pills per day)
Trial: 33008855
Drug: 4-event regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-event regimen (4 pills per day)
Trial: 33008855
Drug: Chewable calcium
RxNorm normalized name: Chewable Calcium
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable calcium supplements
Trial: 32111803
Drug: MRI after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI after neoadjuvant chemotherapy
Trial: 34903704
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 500 mg metronidazole and 3 × 1.5 g cefuroxime intravenously for 3 days starting on the day before RC
Trial: 33752119
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% plus clonidine (2 mcg/kg, maximum of 100 mcg)
Trial: 37702442
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated group)
Trial: 34973284
Drug: PTC923 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 60 mg/kg
Trial: 34973284
Drug: PTC923 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 20 mg/kg
Trial: 34973284
Drug: Sapropterin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin 20 mg/kg
Trial: 34973284
Drug: PTC923 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 60 mg/kg vs. Sapropterin
Trial: 34973284
Drug: PTC923 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 20 mg/kg vs. Sapropterin
Trial: 34973284
Drug: PTC923 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 60 mg/kg in classical PKU subjects
Trial: 34973284
Drug: PTC923 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 60 mg/kg cofactor responder analysis
Trial: 33290857
Drug: Parenteral oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral oxycodone
Trial: 33290857
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between oxycodone and morphine
Trial: 33485369
Drug: rVSV?G‐ZEBOV‐GP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV?G‐ZEBOV‐GP vaccine (with and without booster dose at 56 days)
Trial: 33485369
Drug: Ad26.ZEBOV,MVA‐FN‐Filo vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV,MVA‐FN‐Filo vaccine regimen (Ad26.ZEBOV first dose, MVA‐FN‐Filo 56 days later)
Trial: 34999321
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron intake below average requirement of 5 mg/day in infants
Trial: 34999321
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily iron intake per body weight (mg/kg)
Trial: 32489080
Drug: Kuntai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsules combined with GnRH-a
Trial: 35748777
Drug: ZOL 30
RxNorm normalized name: Zol
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZOL 30 mg
Trial: 35748777
Drug: SUV 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUV 40 mg
Trial: 32079487
Drug: Radioiodine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine treatment (131I)
Trial: 33298062
Drug: BDP/F/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/F/G
Trial: 33819214
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous ultrasound (3 sessions per week for 7 weeks)
Trial: 33819214
Drug: Far-infrared treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far-infrared treatment (3 sessions per week for 7 weeks)
Trial: 36172719
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative medicine (OMM) - 2 treatments
Trial: 36172719
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative medicine (OMM) - 1 treatment
Trial: 32710204
Drug: Hyperthermic IPEC
RxNorm normalized name: Ipecac
DrugBank: Ipecac (DB13293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic IPEC of cisplatin (75, 100, and 120 mg/m2)
Trial: 32710204
Drug: Normothermic IPEC
RxNorm normalized name: Ipecac
DrugBank: Ipecac (DB13293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic IPEC of cisplatin (75, 100, and 120 mg/m2)
Trial: 32710204
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) with IPEC duration of 1-2 hours
Trial: 32710204
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 and 120 mg/m2) with IPEC duration of 1 hour
Trial: 32710204
Drug: Cisplatin (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75, 100, and 120 mg/m2)
Trial: 34518254
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg for a minimum of 12 weeks before surgery
Trial: 33751727
Drug: Medications (bronchodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications (bronchodilators and inhaled corticosteroids)
Trial: 33751727
Drug: Preventive strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive strategies and treatments that alter the course of disease
Trial: 34808726
Drug: onaBotulinum Toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onaBotulinum Toxin type A injection (100 units)
Trial: 35965162
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen (1,000 mg)
Trial: 35965162
Drug: Intravenous Hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Hydromorphone (0.5 mg)
Trial: 33044990
Drug: Empathetic approach
RxNorm normalized name: Bos taurus sympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empathetic approach in treatment and long-term follow-up
Trial: 32589775
Drug: Remdesivir (RDV)
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir (RDV) 75 mg or 150 mg lyophilized formulation infused over 30 minutes or 2 hours
Trial: 32589775
Drug: Remdesivir (RDV)
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir (RDV) 150 mg once daily for 7 or 14 days
Trial: 32589775
Drug: Remdesivir (RDV)
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir (RDV) single-dose i.v. administration over 2 hours (dose range 3-225 mg)
Trial: 32589775
Drug: Remdesivir (RDV)
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir (RDV) solution and lyophilized formulations
Trial: 34128526
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX) injections
Trial: 32078256
Drug: rIX-FP infusions
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIX-FP infusions
Trial: 32567290
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin A and D supplementation
Trial: 32475359
Drug: Fragmented +
RxNorm normalized name: palmitoyl fragment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmented + Coffee (300 mg caffeine)
Trial: 32475359
Drug: Fragmented (waking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmented (waking hourly for 5 min)
Trial: 32534628
Drug: Adjuvanted AGS-v
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvanted AGS-v vaccine (200 nmol with Montanide ISA 51)
Trial: 32534628
Drug: Vaccine only
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine only AGS-v (200 nmol)
Trial: 36376023
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP) pulse for 3 months
Trial: 36376023
Drug: Antiseizure medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medication (ASM) only
Trial: 32199926
Drug: Routine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prescription of 28 tablets of oxycodone 5 mg
Trial: 32199926
Drug: Reduced prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced prescription of 5 tablets of oxycodone 5 mg
Trial: 33137600
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) alone
Trial: 33137600
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) then Behavioural Activation Therapy (BA) for MDD
Trial: 33137600
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation Therapy (BA) then Cognitive Processing Therapy (CPT)
Trial: 35766588
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (diode laser 940 nm, 31.7 J/cm2 energy density, 1.7 cm2 spot size, 300 mW power, continuous-wave, contact mode)
Trial: 32366992
Drug: Topical rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical rifampicin irrigation
Trial: 32366992
Drug: Topical rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical rifampicin
Trial: 35139574
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist administration the day after hCG triggering
Trial: 33216113
Drug: Nebulized PC786
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized PC786 (5 mg)
Trial: 32757038
Drug: Rhino-Protect ointment
RxNorm normalized name: petrolatum Topical Ointment [Lantiseptic Protective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhino-Protect ointment
Trial: 33371086
Drug: Continuous nursing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nursing treatment scheme based on Omaha system (OS)
Trial: 33371086
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment including general guidance associated with PD and outpatient telephone calls from clinical nurses
Trial: 35241538
Drug: Carboplatin AUC2
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC2 and Paclitaxel (45 mg/m2)
Trial: 33662760
Drug: L-menthol mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol mouth rinse (MENT)
Trial: 33068301
Drug: Traditional antidiabetic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antidiabetic therapy (Control, n=40)
Trial: 36194619
Drug: Oral Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Itraconazole 100 mg/day and topical Terbinafine hydrochloride 1%
Trial: 32965622
Drug: Sexual intercourse
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual intercourse 3–4 times/week with symptomatic treatment
Trial: 32965622
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment only, no sexual intercourse or masturbation
Trial: 32795778
Drug: 15-mg apomorphine
RxNorm normalized name: apomorphine hydrochloride 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg apomorphine sublingual film (APL)
Trial: 32795778
Drug: 2-mg subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg subcutaneous Apo-go
Trial: 35119481
Drug: Lenvatinib once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE
Trial: 35045888
Drug: Ionic-iodine polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in encapsulated form
Trial: 35045888
Drug: Ionic-iodine polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in suspension syrup form
Trial: 35045888
Drug: Ionic-iodine polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic-iodine polymer complex (200 mg of elemental iodine) in throat spray form
Trial: 32682395
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine wound infusion by PCA pump
Trial: 32682395
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline wound infusion by PCA pump (Control)